Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharm II > Lecture 3 > Flashcards

Lecture 3 Flashcards

1
Q

_____ is the Peripheral circulatory failure resulting in underperfusion of tissues. Characteristics include: ______ oxygen delivery to tissues.
_________ in anaerobic metabolism

A

Shock

Decrease oxygen delivery to tissues.
Increase in anaerobic metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

The three types of shock include:

A

Septic, Hypovolemic, and Cardiogenic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What happens to CI, PCWP, and SVR in septic shock?

A

Septic: Increased CI, Decreased PCWP, Decreased SVR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What happens to CI, PCWP, and SVR in hypovolemic shock?

A

Hypovolemic: Dec CI, Dec PCWP, Inc SVR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What happens to CI, PCWP, and SVR in cardiogenic shock?

A

Cardiogenic: Dec CI, Inc PCWP, Inc SVR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

______ is the end result of many conditions. (ischemic heart disease, hypertension) and results in decreased ___________

A

CHF

intracellular cAMP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Decreased intracellular cAMP in CHF results in:

A

Downregulation of Beta receptors

Impaired coupling between beta receptors and adenyl cyclase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

CHF responds to:

A

Responds to preload reduction, afterload reduction, and improved contraction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Low Cardiac Output Syndrome (LCOS) is seen in patients coming off of CPB and is a combination of:

A 
Inadequate oxygen delivery to tissues
Hemodilution
Mild hypocalcemia
Hypomagnesemia
Kaliuresis
Tissue thermal gradients
Variable levels of systemic vascular resistance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Risk factors for Low Cardiac Output Syndrome (LCOS) include:

A

Risk factors: DM, Increasing age, female, pre-op decreased LVEF, increased duration of CPB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Treatment of Low Cardiac Output syndrome includes:

A

positive inotropes to increase the contractility of normal and stunned myocardium
hypotension, unlike CHF, responds poorly to vasodilators alone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Goal of Low Cardiac Output syndrome:

A

increase levels of O2 delivery

increase O2 consumption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

cAMP Dependent Positive Inotropes include:

cAMP Independent Positive Inotropes include:

A

cAMP Dependent:
Beta Agonists
Dopaminergic Agonists
Phosphodiesterase Inhibitors

cAMP Independent:
Cardiac Glycosides
Calcium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Hemodynamic effects of positive inotropes include:

A

Increased contractility with:
Increased SV
Often decreased LVEDP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

T/F In the failing circulation, effects of inotropes are likely to be more pronounced.

A

TRUE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Complications of Isoproterenol:

A

Tachyarrythmias

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Complications of high dose NE and Epi for prolonged periods with persistent low CO:

A

will decrease perfusion to many tissue beds and contribute to renal failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Use Digoxin cautiously in patients with:

A

hypokalemia, renal failure, bradycardia, drug interactions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Arrhythmogenic potential of positive inotropes:

A

Dobutamine<Isoproterenol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

For Beta agonists cAMP increases Ca influx via slow channels and increases Ca sensitivity of Ca-regulatory proteins. This Increase the force of:

A

contraction and velocity of relaxation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Epinephrine is the prototypical catecholamine that stimulates:

A

Alpha 1, Beta 1, Beta 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Low dose epinephrine stimulates _____ and is essentially a _______

A

Beta 2, vasodilator

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Intermediate dose epinephrine stimulates _____, which ___________

A

Beta 1
which is an inotrope
increases HR and contractility and increases CO and increases automaticity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

High dose epinephrine stimulates ____ and is a potent _______.

A

Alpha 1
Vasoconstrictor

Most potent activator of Alpha-1 receptors
Potent vasoconstrictor including cutaneous, splanchnic and renal vascular beds
Used to maintain myocardial and cerebral perfusion
Increases Aortic dBP.
Reflex bradycardia can occur
Vasoconstrictor.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Norepinephrine is primarily an __________

A

Alpha 1 agonist

Beta-1 effects are overshadowed by its Alpha-1 effects
Beta-2 effects are minimal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

T/F: Cardiac output decreases at low doses, but at higher doses may increase because of increased afterload and baroreceptor-mediated reflex bradycardia

A

FALSE!
Cardiac output may INCREASE at low doses, but at higher doses may DECREASE because of increased afterload and baroreceptor-mediated reflex bradycardia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

NE binds to _________ more readily than ____

A

Binds to Alpha-1, Alpha-2 and Beta-1 receptors more readily than Beta-2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Isoproterenol has ______ receptor effects, No _____ effects.

A

BETA 1 and BETA 2
NO ALPHA

Increases HR , contractility, B.P., and cardiac automaticity
Decreases SVR and diastolic BP

29
Q

The net effect of Isoproterenol is

A

increased CO and decreased MAP

30
Q

Isoproterenol should not be used in patients with

A

Cardiogenic shock and with ischemic heart disease

31
Q

Uses of Isoproterenol include:

A

Chemical pacemaker after heart transplant or in complete heart block
Bronchospasm management during anesthesia
Maybe used to attempt to decrease PVR in patients with pulmonary hypertension and RV failure.

32
Q

Dobutamine is a synthetic catecholamine with structural characteristics of:

A

Dopamine and Isoproterenol

33
Q

Dobutamine acts primarily on

A

Beta 1 receptors with small effects on Beta 1 and Alpha 1 receptors
No clinically significant vasoconstrictor activity.
Small increase in heart rate compared to isoproterenol.
Less likelihood of adverse increase in myocardial O2 requirements.
Dilates coronary vasculature.
No dopaminergic receptor activation.
Increases renal blood flow by increasing C.O.

34
Q

Dobutamine has dose dependent increases in _____ and decrease in _______.

A

HR and CO and decrease in filling pressures
Inotropic properties with less dysrhythmogenic activity, doses >10 mcg/kg/min may predispose to tachycardia and cardiac dysrhythmias

35
Q

D1 ultimately ______ cAMP, which results in ______________.

A

activates
Smooth muscle of blood vessels: vasodilatation
Naturesis, Diuresis

36
Q

D2 ultimately ______ cAMP, which results is

A

inhibits
Presynaptic: Inhibit NE release and promote vasodilation
Attenuate the beneficial effects of DA on renal blood flow

37
Q

Dose dependent effects of Dopamine:

A

0.5-3 mcg/kg/min dopamine effect (DA1 and DA2)
3-10 mcg/kg/min beta effect
10-20 mcg/kg/min beta and alpha effects
Over 20 mcg/kg/min alpha effects

Relationship between DA dose and effect is associated with some individual to individual variability.

38
Q

T/F Low dose dopamine is renal protective

A

FALSE
Increases RBF, GFR, Na+ excretion and urine output
BUT NOT RENAL PROTECTIVE

39
Q

Dopamine is often used in clinical situations where the patient presents with:

A

Decreased C.O.
Decreased systemic B.P.
Increased L.V. end-diastolic pressure

40
Q

________ interferes with the ventilatory response to _______.

A

Dopamine

hypoxemia

41
Q

High doses of Dopamine ______ release of insulin, which causes

A

inhibit

hyperglycemia

42
Q

Dopamine and Dobutamine must be mixed in

A

D5W

43
Q

Phosphodiesterase III inhibitors:

A

Slow the metabolism of cAMP to 5’-AMP increasing intracellular cAMP concentrations.
Increase the Ca sensitivity of contractile proteins
Increase Ca influx
Antagonize adenosine

44
Q

Inamrinone is a PD3 that has dose dependent increases in ____&___ and decreases in ____&____ after CABG.

A

Dose-dependent increases in SV and CI and decreases in SVR and PVR after CABG

More effective with fewer complications than dobutamine during separation from CPB

45
Q

In patients with poor LV function, Inamrinone is as effective as ______, but both are more superior to either drug alone.

A

epinephrine

Inamrinone increases intrapulmonary shunting and decreases PaO2.

46
Q

Adverse reactions of Inamrinone include:

A 
Thrombocytopenia (10%)
Elevated LFTs
Arrhythmias
Do NOT administer to patients AS 
May aggravate outlet obstruction in patients with IHSS
47
Q

Milrinone is preferred to inamrinone because:

A

Inotropic and vasodilator properties similar to inamrinone but 15-20 times more potent, with a shorter t½ and without the risk of thrombocytopenia.
Decrease dose in renal failure

48
Q

Side effects of milrinone include:

A

Headache, hypotension, syncope.

Ventricular arrhythmias.

Increased ventricular response rate in A. Fib/ . Flutter.

49
Q

Effects of glucagon:

A

Acts at a receptor other than beta to increase cAMP (Glucagon receptor?)
Increases CI, HR, BP while decreasing SVR and LVEDP
Useful for cardiac failure particularly when precipitated by beta-adrenergic blockade
Use is limited due to expense and side effects (N/V, increased blood sugar, increased coronary and pulm. vascular resistance)

50
Q

Effects of digoxin:

A

Cardiac glycoside:

Positive inotrope.
Negative dromotrope.
Negative chronotrope

51
Q

Direct myocardial action of digoxin:

A

Inhibits Na-K ATPASE increasing intracellular Na and indirectly intracellular Ca.
Ca may bind to troponin-C, increasing inotropy
In CHF, dig increases LV shortening and EF
Not effective for acute management of LCOS

52
Q

Uses of digoxin:

A

Positive Inotrope for the treatment of mild to moderate heart failure
Often used in combination with a diuretic and ACE Inhibitor.
Control of ventricular response rate with chronic A. Fib.

53
Q

The toxic level of digoxin is

A

Plasma levels > 3ng/mL.
Treating CHF keep < toxic level.
Treating A. fib. Treat to results (desired ventricular rate)

54
Q

Digoxin toxicity is associated with

A

decrease in intracellular potassium

55
Q

Predisposing causes of digoxin toxicity:

A 
Hypokalemia
Hypomagnesemia
Hypoxemia
Hypercalcemia
Hypothyroid
56
Q

Presentation of digoxin toxicity:

A 
Presentation:
Early: anorexia, N/V
PVCs
Paroxysmal atrial tachycardia with block
Most common dysrrhythmia.
Mobitz type II A-V- block
V. fib. 
Most frequent cause of death
57
Q

Treatment of digoxin toxicity:

A

Correction of predisposing causes:
Supplemental potassium.
Supplemental magnesium.
Correct hypoxemia.

Administration of drugs:
Phenytoin or lidocaine to suppress ventricular dysrhythmias.
Atropine to increase heart rate.
Beta blocker use to suppress increased automaticity may be limited by increased AV node refractoriness when conduction blockade is present.

Temporary pacing if complete heart block is present.

58
Q

After administration of Digibind, are digoxin levels accurate?

A

NO, Do not check levels. Levels are useless for several days

59
Q

Digoxin drug interactions:

A 
Drugs Dec Clearance
Quinidine
Amiodarone
Verapamil
Propafenone
Coreg
Cyclosporine
Conivaptan
Enhance Dig Abs
Macrolides
PPIs
“Conazoles”
Ranolazine
Dec Dig Abs
Resin binders
Acarboes/miglitol
Kaolin-pectins
Reglan
Sulfasalazine
Sucralfate
60
Q

Effects of calcium:

A

Ca above the normal range, improves contractility of isolated cardiac muscle.

Ca increases systemic vascular resistance. Ca interacts with vasoactive drugs.

Ca can inhibit Beta agonists by direct inhibition of adenyl cyclase

Bolus dosing of Ca has no consistent effect on CO coming off CPB.

61
Q

Catecholamine Complications:

A 
Local tissue ischemia from SQ infiltration of inoconstrictors. 
Increased myocardial oxygen consumption
Enhance lipolysis and gluconeogenesis
Alter electrolyte concentrations
Activate coagulation
Override microvascular control mechanisms
Alter distribution of CO
Increase myocardial work
Increase the risk of cardiac arrhythmias
62
Q

Therapeutic Plan for Low CO:

A

Optimize Heart Rate and Rhythm
Optimize Preload
If BP acceptable after increasing preload, administer an arteriolar dilator to increase SV (Optimize afterload).
For low BP, add an Inotrope

63
Q

Positive inotrope selection for Pulmonary and or systemic HTN:

A

dobutamine, inamrinone or milrinone, isoproterenol

64
Q

Positive inotrope selection for low SVR:

A

NE, DA, epi

65
Q

Positive inotrope selection for normal SVR and PVR:

A

DA, epi

66
Q

Positive inotrope selection for Tachycardia:

A

inamrinone or milrinone, calcium, NE, epi

67
Q

Persistent low CO or myocardial ischemia with maximal medical therapy indicates the need for:

A

IABP, LVAD

68
Q

ALARM-AF Trial:

A

Lower in house mortality for patients receiving vasodilator + diuretic (7.6%) vs diuretic alone (14.2%)
Greater in house morality for IV inotropes (25.9%) vs No inotropes (5.2%)
1.5 fold increase for patients receiving dopamine or dobutamine, 2.5 fold increase for patients receiving NE or Epi

Pharm II (3 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions